Stock Forecast

  Avadel Pharmaceuticals plc ( AVDL) Stock. Should you Buy or Sell?    $ 6.19

0.15 (2.37 %)

Avadel Pharmaceuticals plc Analysis

Updated on 10-09-2022
Symbol AVDL
Price $6.19
Beta 1.514
Volume Avg. $799.99 thousand
Market Cap $370.12 M
52 Week Range $1.05 - $11.59

Avadel Pharmaceuticals plc opened the day at $6.19 which is +'2.37 % on yesterday's close. Avadel Pharmaceuticals plc has a 52 week high of $11.59 and 52 week low of $1.05, which is a difference of $10.54. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $370.12 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Avadel Pharmaceuticals plc for $370.12 M, it would take 15 years to get your money back. Avadel Pharmaceuticals plc are in the Drug Manufacturers—Specialty & Generic space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


Avadel Pharmaceuticals plc Stock Forecast - Is Avadel Pharmaceuticals plc a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreStrong Sell
ROA ScoreSell
DE ScoreStrong Buy
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationNeutral

Growth and Value

PE Ratio -2.724
Dividend Yiel 0.000
Net Profit Margin 0.000

Valuing Avadel Pharmaceuticals plc

Price Book Value Ratio -109.676 Price To Book Ratio -109.676
Price To Sales Ratio 0.000 Price Earnings Ratio -2.724

How liquid is Avadel Pharmaceuticals plc

Current Ratio 2.720
Quick Ratio 2.253


Debt Ratio 1.021 Debt Equity Ratio -48.400
Long Term Debt To Capitalization 1.031 Total Debt To Capitalization 1.025

Latest news about Avadel Pharmaceuticals plc

Avadel's LUMRYZ: A Good Night's Sleep For Narcolepsy Patients

Avadel Pharmaceuticals' LUMRYZ (FT218), with its essential once daily dosing, has snagged a tentative approval from the FDA. Once finally approved, LUMRYZ has serious prospects for knocking off Jazz's flawed blockbuster XYREM/XYWAV duopoly.

Date : 06/09/2022

Avadel Pharmaceuticals: Navigating Through The Uncertainty

Avadel Pharmaceuticals goes into the spotlight today. This small biopharma company recently got 'tentative' FDA approval for its flagship drug but is still waiting on one patent challenge to move forward to commercialization.

Date : 05/09/2022

Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q2 2022 Results - Earnings Call Transcript

Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q2 2022 Earnings Conference Call August 9, 2022 8:00 AM ET Company Participants Brandi Robinson - Senior Vice President of Corporate Affairs Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical & Clinical Affairs Richard Kim - Chief Commercial Officer Tom McHugh - Senior Vice President & Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Oren Livnat - H.C. Wainwright David Amsellem - Piper Sandler Adam Evertts - LifeSci Capital Chase Knickerbocker - Craig Hallum Operator Greetings, and welcome to Avadel Pharmaceuticals' Second Quarter 2020 Earnings Call.

Date : 09/08/2022

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9

DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, August 9, 2022, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2022.

Date : 02/08/2022

Avadel Cuts Workforce, Optimizes Cost Structure To Support This

Avadel Pharmaceuticals plc (NASDAQ: AVDL) announced its steps to explore every available pathway to accelerate the FDA approval of its lead drug candidate, FT218, before June 2023.  Avadel has received and agreed upon what is expected to be a final label and is completing.

Date : 30/06/2022

About Avadel Pharmaceuticals plc

CEO : Mr. Gregory Divis
Sector : Healthcare
Industry : Drug Manufacturers—Specialty & Generic

Website :

Exchange : NASDAQ Global Market

Description :

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

My Newsletter

Sign Up For Updates & Newsletters